银屑病一线生物制剂失败后二线生物制剂的持续性:法国全国队列研究
基于法国健康保险数据库的全国队列研究,纳入8693例一线生物制剂停用后直接启用二线生物制剂的银屑病患者,比较四类二线生物制剂的长期持续性。 propensity评分加权Cox模型显示,二线IL-23i持续性长于TNFi、IL-17i和IL-12/IL-23i,但所有生物制剂3年持续性均较低。
要点
- 二线IL-23i的持续性优于TNFi、IL-17i和IL-12/IL-23i。
- 一线使用IL-17i后,二线IL-12/IL-23i、IL-17i与TNFi持续性无差异。
- 所有生物制剂1年和3年持续性率分别为60%和30%。
核心结论
- 真实世界研究提示,作为银屑病二线治疗,IL-23i的持续性长于TNFi、IL-17i和IL-12/IL-23i,但所有生物制剂3年持续性仍较低。
研究设计与样本
- 法国全国队列研究,基于法国健康保险行政医疗数据库链接医院出院数据库,纳入2015年1月1日至2021年12月31日期间启动二线生物制剂的成人银屑病患者8693例,随访截至2022年6月30日。
主要发现
- 纳入8693例患者,平均(SD)年龄50(14)岁,50.5%为男性;2824例(32.5%)起始TNFi,1561例(18.0%)起始IL-12/IL-23i,2707例(31.1%)起始IL-17i,1601例(18.4%)起始IL-23i。
- 总体1年和3年持续性率分别为60%和30%。
- 加权调整后,二线IL-12/IL-23i(HRw 0.68,95% CI 0.62-0.76)、IL-17i(HRw 0.70,95% CI 0.64-0.78)和IL-23i(HRw 0.36,95% CI 0.31-0.42)的持续性均长于TNFi;但一线使用IL-17i后,二线IL-12/IL-23i、IL-17i与TNFi的持续性无差异。
- 无论一线治疗如何,二线IL-23i的持续性长于IL-12/IL-23i(HRw 0.53,95% CI 0.44-0.63)和IL-17i(HRw 0.51,95% CI 0.44-0.60);IL-12/IL-23i与IL-17i之间无差异(HRw 0.97,95% CI 0.87-1.09)。
关键数值与推荐
- 持续性定义为前次处方覆盖期后超过90天未续配同一治疗。
- 比较采用倾向评分加权Cox模型(逆概率治疗加权)并调整特定系统性非生物制剂(时依变量)。
临床怎么用
- 该真实世界研究提示,银屑病二线治疗选择IL-23i可能与更长的持续性相关。
- 一线使用IL-17i后,二线选择IL-12/IL-23i、IL-17i或TNFi的持续性无差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many biologics are available for psoriasis and have been compared in real-life studies based on their persistence (i.e. time between initiation and discontinuation). However, after first-line biologic failure, data are lacking on the choice of second-line biologic among the four available classes [tumour necrosis factor inhibitors (TNFi); interleukin (IL)-12/IL-23 inhibitor (IL-12/IL-23i); IL-17 inhibitors (IL-17i); and IL-23 inhibitors (IL-23i)]. OBJECTIVES: To compare the long-term persistence of available second-line biologics in psoriasis according to prior exposure. METHODS: This nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to a hospital discharge database. Participants were adults with psoriasis, defined as having at least two prescriptions of a topical vitamin D derivative within a 2-year period, with initiation of a second-line biologic between 1 January 2015 and 31 December 2021. We included patients who initiated a second-line biologic directly after first-line discontinuation (i.e. without a 'washout' period). The end of follow-up was 30 June 2022. Discontinuation was defined as > 90 days without filling a prescription for the same treatment after the period covered by the previous prescription. Comparison of persistence by biologic class involved using propensity score-weighted Cox models (inverse probability treatment weighting) and adjustment of specific systemic nonbiologics (time-dependent variables). RESULTS: We included 8693 patients [mean (SD) age 50 (14) years; 50.5% male]; 2824 (32.5%) started TNFi, 1561 (18.0%) IL-12/IL-23i, 2707 (31.1%) IL-17i and 1601 (18.4%) IL-23i. Overall, 1- and 3-year persistence rates were 60% and 30%, respectively. After weighting and adjustment, persistence was longer with IL-12/IL-23i [weighted hazard ratio (HRw) 0.68, 95% confidence interval (CI) 0.62-0.76)], IL-17i (HRw 0.70, 95% CI 0.64-0.78) and IL-23i (HRw 0.36, 95% CI 0.31-0.42) than TNFi, except after first-line IL-17i treatment, with no difference between IL-12/IL-23i, IL-17i and TNFi second-line persistence. Persistence was longer with IL-23i as a second-line treatment than IL-12/IL-23i (HRw 0.53, 95% CI 0.44-0.63) and IL-17i (HRw 0.51, 95% CI 0.44-0.60), regardless of first-line treatment, with no difference seen between IL-12/IL-23i and IL-17i (HRw 0.97, 95% CI 0.87-1.09). CONCLUSIONS: This real-life study suggests the longer persistence of IL-23i than TNFi, IL-17i and IL-12/IL-23i as second-line treatment for psoriasis. Persistence rates for all biologics remained low at 3 years.
引用
- Marcombes C, Penso L, Weill A, et al. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS). Br J Dermatol. 2023. PMID: 37479503. doi:10.1093/bjd/ljad248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。